Clinical Trial Update: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of FCX-007 for recessive dystrophic epidermolysis bullosa (RDEB) was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• FCX-007

Snippet

Sponsor: Castle Creek Biosciences, LLC. | Conditions: Epidermolysis Bullosa Dystrophica, Recessive | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-09-16